Endocrine Dysfunction from Immune Checkpoint Inhibitors: Pearls and Pitfalls in Evaluation and Management

Anupam Kotwal, Jordan E. Perlman, Whitney S. Goldner, Alissa S Marr, Jennifer S. Mammen

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Immune checkpoint inhibitors (ICPis) have proven extremely efficacious in cancer therapy but also lead to a plethora of immune-related adverse events (irAEs). The endocrine irAEs are not only quite common but also may pose a challenge to the clinician while managing a patient with cancer treated with ICPis. The clinical features of endocrine dysfunction are usually nonspecific and may overlap with concurrent illnesses, underlying the importance of accurate hormone testing and efforts toward case-finding. The management of endocrine irAEs is unique in the focus being on hormone replacement rather than curtailing the autoimmune process. Although the management of thyroid irAEs appears straightforward, adrenal insufficiency and insulin-dependent diabetes can be life-Threatening if not promptly recognized and treated. This clinical review synthesizes the studies to provide pearls and pitfalls in the evaluation and management of endocrine irAEs with specific reference to guidelines from oncologic societies.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalJCO Oncology Practice
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2023

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Endocrine Dysfunction from Immune Checkpoint Inhibitors: Pearls and Pitfalls in Evaluation and Management'. Together they form a unique fingerprint.

Cite this